

Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy

NCT06579469

| | |
|------------|---------------------------------------|
| Status | RECRUITING |
| Sponsor | St. Jude Children's Research Hospital |
| Enrollment | 100 participants |

Key Eligibility Criteria

Inclusion (3)

- Participants must have received an initial systemically-administered CAR T cell infusion within the last 1-3 months (+/- 14 days).
- Initial infusion is defined as the first administration of a CAR T cell product the participant has not previously received OR receipt of a CAR T cell product previously received after an interval allogeneic HSCT.
- Age ≥ 30 years at CAR T cell infusion.

Exclusion (4)

- Active malignancy other than the disease under study.
- Planned consolidative HSCT within 3 months post CAR T cell infusion.
- Received or planned additional disease directed therapy post CAR T cell infusion.
- Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.

Locations (3 total)

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Children's Hospital of Wisconsin., Milwaukee, Wisconsin, United States